FATE News and Press, Fate Therapeutics Inc. From 08/08/23

Phase 1 Study Start-up Ongoing for FT522 ADR-armed, CD19-targeted CAR NK Cell Program for B-cell Lymphoma; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Conditioning Chemotherapy 2H23 IND Submission Planned under ONO Collaboration for FT825/ONO-8250; HER2-t...

SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived c...

NEW ORLEANS, June 16, 2023 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Fate Therapeutics, Inc. (NasdaqGM: FATE). On...

2023-06-16 15:53:25 ET Shares of Fate Therapeutics (NASDAQ: FATE) were up by 23.7% for the week as of Friday afternoon, after being as high as 30.8% for the week, according to data provided by S&P Global Market Intelligence . The clinical-stage biotech is still down more...

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Fate Therapeutics, Inc. (NasdaqGM: FATE). On April 2, 2020, the Company announced its entry i...

SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellula...

2023-05-23 13:40:20 ET Summary Shares of off-the-shelf cell therapy concern Fate Therapeutics, Inc. have cratered 95% since reaching an all-time high in January 2021, punctuated by the termination of its Johnson & Johnson deal. The company has essentially hit the reset button,...

2023-05-03 20:34:05 ET Fate Therapeutics, Inc. (FATE) Q1 2023 Earnings Conference Call May 03, 2023 05:00 PM ET Company Participants Scott Wolchko - President and Chief Executive Officer Ed Dulac - Chief Financial Officer Wayne Chu - Chief Medical Officer Bob...

2023-05-03 16:05:12 ET Fate Therapeutics press release ( NASDAQ: FATE ): Q1 GAAP EPS of -$0.19 beats by $0.47 . Revenue of $58.98M (+220.5% Y/Y) beats by $25.45M . For further details see: Fate Therapeutics GAAP EPS of -$0.19 beats by $0.47, revenue of $5...

Dose Escalation Ongoing in Landmark Phase 1 Study of FT819 CD19-targeted 1XX CAR T-cell Program; Interim Clinical Data Demonstrated Favorable Safety Profile and Complete Responses in Aggressive Large B-cell Lymphoma FT576 BCMA-targeted CAR NK Cell Program Accruing Patients in Multi-dose E...